NEW YORK, January 29, 2021 / PRNewswire / –
WHY: Rosen Law Firm, a global investment rights law firm, announces that a class action lawsuit will be filed on behalf of the buyers of AstraZeneca PLC (NASDAQ: AZN) securities between May 21, 2020 and November 20, 2020, inclusive (the “class time”). The lawsuit seeks to recover damage to AstraZeneca investors under federal securities laws. A class action lawsuit has already been filed. If you want to be the main complaint, you have to move the Court not to exceed March 29, 2021.
SO WHAT: If you purchased AstraZeneca securities during Class Time you may be entitled to compensation without incurring any costs or expenses through a contingent tax settlement.
WHAT TO DO: To join the AstraZeneca class action, visit http://www.rosenlegal.com/cases-register-2027.html or call Phillip Kim, Esq. no fees at 866-767-3653 or email [email protected] no [email protected] for information about the class activity. A class action lawsuit has already been filed. If you want to be the main complaint, you have to move the Court not to exceed March 29, 2021. A chief planner is a representative party acting on behalf of other class members in administering the law.
WHY: We encourage investors to choose certified advice with a history of success in management positions. Issuing companies often do not have comparable knowledge or resources. Rosen Law Firm represents investors worldwide, focusing their use in securities class actions and legalizing shareholder sub-shares. Rosen Law Firm has executed the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was ranked at No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017. The firm has been ranked in the top 3 annually since 2013 and has get back hundreds of millions of dollars to investors. In 2019 alone the company took over $ 438 million for investors. In 2020 founding partner Laurence Rosen named by the law360 as the Titan Bar of Plaintiffs. Many of the firm’s lawyers are recognized by Lawdragon and Super Lawyers.
CASE INFORMATION: According to the lawsuit, defendants during the Class Period made false and / or misleading statements and / or failed: (1) initial clinical trials for AZD1222, a hopeful coronavirus vaccine, have suffered a critical manufacturing error , resulting in a large number of trial participants receiving half the planned dosage; (2) clinical trials for AZD1222 involved smallpox work of different patient subgroups, each with slightly different treatments, weakening validity and reversing the conclusions reached. could be drawn from the clinical data across these different patient numbers; (3) Some clinical trial participants for AZD1222 did not receive a second dose at the indicated intervals, but instead received a second dose up to several weeks after the dose was delivered according to design the original of the test; (4) AstraZeneca had failed to include a large number of patients over the age of 55 in its clinical trials for AZD1222, despite the fact that this patient population was particularly vulnerable. to the effects of COVID-19 and thus a high priority target market for the drug; (5) AstraZeneca clinical trials for AZD1222 had been hampered by widespread design defects, errors in performance, and failure in proper coordination and communication with regulatory authorities and the general public; (6) as a result of the foregoing, the clinical trials for AZD1222 were not conducted in accordance with industry best practices and relevant standards and the data and possible conclusions from the trials were not available. clinical but minimal resource; and (7) as a result of what has been said, AZD1222 did not appear to have been approved for commercial use in United States in the short term, one of the largest potential markets for the drug. Once the real details entered the market, the lawsuit alleges that investors suffered damage.
To join the AstraZeneca class action, visit http://www.rosenlegal.com/cases-register-2027.html or call Phillip Kim, Esq. no fees at 866-767-3653 or email [email protected] no [email protected] for information about the class activity.
No classes were confirmed. Until a class is confirmed, you will not be represented by an adviser unless you book one. You can choose a consultant of your choice. You can also remain an absent class member and do nothing at this stage. An investor’s ability to share in any future improvement is not dependent on serving as a key complaint.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Lawyer advertising. Previous results do not guarantee a similar result.
——————————-
Contact information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Law Firm Rosen, PA
275 Madison Avenue, 40th floor
New York, NY 10016
Phone: (212) 686-1060
Hole free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com
SOURCE Rosen Law Firm, PA
Related Links
www.rosenlegal.com